Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

Abroad (travel likely)Recruiting

Conditions

Waldenström's Macroglobulinemia · Chronic Lymphocytic Leukemia · Marginal Zone Lymphoma · Follicular Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Universitätsklinikum Salzburg, Klinik für Innere Medizin III, Salzburg, Austria
Contact: Study coordinator (Richard Greil, Prof.) · r.greil@salk.at · +435725525800
Lübecker Onkologische Schwerpunktpraxis, Lübeck, Schleswig-Holstein, Germany
Contact: Study coordinator (Jens Kisro, Dr.) · jens-kisro@t-online.de · +4945170797226

Study leads

Jens Kisro, Dr.
Principal Investigator
Lübecker Onkologische Schwerpunktpraxis
Richard Greil, Prof.
Principal Investigator
Universitätsklinikum Salzburg, Klinik für Innere Medizin III

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Chronic Lymphocytic Leukemia (CLL) · Diffuse Large B-cell Lymphoma (DLBCL) · Follicular Lymphoma (FL)

Abroad (travel likely)Recruiting

Freiburg im Breisgau, Germany

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

Waldenström's Macroglobulinemia

Abroad (travel likely)RecruitingPHASE4

Beijing, China · Guangzhou, China

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Lymphoplasmacytic Lymphoma · Waldenstrom Macroglobulinemia

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States